Literature DB >> 714115

Hemodynamic assessment of amrinone. A new inotropic agent.

J R Benotti, W Grossman, E Braunwald, D D Davolos, A A Alousi.   

Abstract

Amrinone, a new bipyridine derivative, exerts a positive inotropic action in experimental preparations and is effective when administered orally to dogs. To assess its immediate effects in man, we studied by cardiac catheterization the hemodynamic responses to amrinone (1.85 to 3.5 mg per kilogram given intravenously) in eight patients with congestive heart failure already receiving full doses of digitalis. the following statistically significant (P less than 0.01) effects were noted: cardiac index increased from a mean +/- 1 S.D. of 1.8 +/- 0.3 to 2.6 +/- 0.3 liters per minute per square meter; peak rate of left ventricular pressure rise rose from 849 +/- 233 to 1206 +/- 456 mm Hg per second; left ventricular end-diastolic pressure fell from 25 +/- 9 to 14 +/- 7 mm Hg; pulmonary-capillary pressure fell from 28 +/- 8 to 15 +/- 4 mm Hg; and right atrial pressure fell from 12 +/- 6 to 7 +/- 5 mm Hg. Mean heart rate was unchanged, and aortic mean pressure declined slightly (86 +/- 10 to 80 +/- 7 mm Hg, P less than 0.025). No toxicity was observed. Amrinone, whose mechanism of action has not yet ben defined, warrants further study as a possible treatment for heart failure.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 714115     DOI: 10.1056/NEJM197812212992501

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  58 in total

1.  Noninvasive assessment of the inodilator action of amrinone in healthy man.

Authors:  C de Mey; D Enterling; G Hanft
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Subcellular mechanism of the positive inotropic effect of a new quinolinone derivative OPC-8490 on the dog ventricular myocardium.

Authors:  M Endoh; H Satoh; I Norota; K Hirano; T Hosokawa
Journal:  Heart Vessels       Date:  1991       Impact factor: 2.037

Review 3.  The appropriate use of inotropes in shock.

Authors:  M H Rosenthal
Journal:  Can J Anaesth       Date:  1990-05       Impact factor: 5.063

Review 4.  Treatment of end stage dilated cardiomyopathy.

Authors:  J B O'Connell; C K Moore; H C Waterer
Journal:  Br Heart J       Date:  1994-12

5.  Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside.

Authors:  B E Jaski; M A Fifer; R F Wright; E Braunwald; W S Colucci
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

6.  Cardiogenic shock. Current concepts in management.

Authors:  K Balakumaran; P G Hugenholtz
Journal:  Drugs       Date:  1986-10       Impact factor: 9.546

7.  Acute hemodynamic effects and preload-dependent cardiovascular profile of the partial phosphodiesterase inhibitor nanterinone in patients with mild to moderate heart failure.

Authors:  W J Remme; M van der Ent; G L Bartels; D van Schelven; D C van Hoogenhuyze; X H Krauss; H A Kruijssen; C J Storm
Journal:  Cardiovasc Drugs Ther       Date:  1996-05       Impact factor: 3.727

8.  Beneficial effect of amrinone on murine cardiac allograft survival.

Authors:  T Hirozane; A Matsumori; Y Furukawa; S Matsui; Y Sato; Y Matoba; S Sasayama
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

Review 9.  The role of vasodilator therapy in the treatment of severe chronic heart failure.

Authors:  M Packer
Journal:  Drugs       Date:  1986       Impact factor: 9.546

10.  The effects of amrinone on platelet count, survival and function in patients with congestive cardiac failure.

Authors:  P T Wilmshurst; S F Al-Hasani; M J Semple; A S Hamblin; P G Kioy; G F Lucas; G F Savidge; M M Webb-Peploe
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.